Cefprozil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains. Infections include: Lower respiratory tract infections: acute bronchitis, acute exacerbations of chronic bronchitis, community acquired pneumonia. Upper respiratory tract and ear infections: otitis media, sinusitis, tonsillitis and pharyngitis. Uncomplicated skin and soft tissue infections.
Second generation Cephalosporins
Adult: 500 mg daily as a single or in 2 divided doses, increased to 500 mg bid if necessary. Duration: 10 days. Child (6 month to 2 year): For otitis media: 15 mg/kg 12 hrly. For acute sinusitis: 7.5 mg/kg or 15 mg/kg 12 hrly. For pharyngitis or tonsillitis: 7.5 mg/kg 12 hourly. Child (>2 yr): For skin and skin structure infections: 20 mg/kg daily. Max: 1 g daily.
Hypersensitivity to cephalosporin antibiotics. History of hypersensitivity to penicillins and GI disease esp colitis. Renal impairment. Pregnancy and lactation.
Cefprozil was usually well tolerated in controlled clinical trials. The most common adverse effects of cefprozil are diarrhea, nausea, vomiting, abdominal pain, rash, urticaria, dizziness, hyperactivity, insomnia, confusion etc.
Pregnancy category B. There are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Small amounts of cefprozil (<0.3% of dose) have been detected in human milk following administration of a single 1 gram dose to lactating women. Caution should be exercised when cefprozil is administered to a nursing woman, since the effect of cefprozil on nursing infants is unknown.
.png&w=384&q=75)